Microbial API Market Size was valued at USD 58.3 Billion in 2023. The microbial API market industry is projected to grow from USD 62.3 Billion in 2024 to USD 100.17 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.00% during the forecast period (2024 - 2032). One of the main market drivers driving the need for microbial APIs is anticipated to be the increasing prevalence of chronic illnesses, such as Alzheimer's disease and others.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Growing chronic diseases internationally causes a permanently raised level of demand for APIs containing microorganisms. The pharmaceutical industry actively looks for new treatments as it is now struggling with the growing list of such diseases as heart disease, diabetes or neurological problems. According to the World Health Organization (WHO) statistics, diseases without communication are responsible for the mortality of a total of 71% of deaths in the world. In the given paragraph, the fact that cardiovascular diseases caused more than 18 million deaths around the world in 2021 is of crucial importance, as it shows the microbial APIs importance in creating essential medicines. Besides, the availability of microbial APIs to develop drugs to treat many diseases is enhanced. Chronic diseases account for a considerable share of illness and death worldwide and therefore the efficient treatment is the most important issue. The pharmaceutical sector is taking the initiative by increasing drug research and development and creating medications specifically intended to hit the complexities of chronic diseases with the help of microbial APIs. Such an expanding demand for these products emphasizes the role of microbial APIs in revolutionizing the pharmaceutical industry and its response to tackling the incurring problem of chronic illnesses.
The market CAGR for microbial API is expanding significantly due to the growing need for biosimilar and generic medications. Because these pharmaceuticals are an affordable substitute for pricey brand-name treatments, they are essential to lowering the cost of healthcare. The Association for Accessible Medicines estimates that in 2022 alone, savings to the U.S. healthcare system from generic and biosimilar medications were a startling $408 billion. This pattern is anticipated to persist as new generic and biosimilar product introductions are made possible by the expiration of brand-name medicine patents, which will increase consumer demand. For many of these medications, microbial fermentation provides an economical and scalable production process, which makes it a desirable choice for producers looking to fulfill the rising demand and support more people having access to affordable healthcare.
It can be seen that this development in microbial API world market takes on the direction of implementing earth-friendly and environment-preserving manufacturing approaches. Rising environmental concerns and a very prevalent development in the area of sustainable, biopharmaceutical industry are the leading factors. These widely used traditional chemical synthesis techniques require large amounts of energy, lead to massive waste generation, and they are dependent on non-renewable resources. In contrast to microbial fermentation, the latter process possesses some advantages with respect to the environment. It gives out no waste or very little, greatly reduces energy consumption, and uses renewable resources such as corn or sugarcanes. WHO is one of the leading agencies, it is aggressive on the campaign for environment-friendly activities in the pharmaceutical industry. WHO declared in a report from 2022 that the aim of the organization is to 'reduce the environmental impact of the life cycle of medicines by 25 % by the year 2030,' which is clear evidence of the growth of microbial fermentation technology. As a result of the incentives that the government provides for the sustainable manufacturing and due to the fact that microbial fermentation has become the primary method of API production for the biopharmaceuticals sector, the companies are building on it. While the addition of microbial fermentation is a very strong aspect, microbiome APIs are forecasted to dominate the microbial API market going forward. Thus, driving the microbial API market revenue.
The Microbial API Market segmentation, based on host includes Mammalian, Bacterial, and Fungal. In 2023, the mammalian segment dominated the market. The manufacturing of active pharmaceutical ingredients utilizing mammalian cell cultures is referred to as the "mammal segment" in the microbial API market. Complex biologics and therapeutic proteins must be manufactured using this method. Continuous improvements in the technology of mammalian cell culture, yield optimization, and the efficient manufacture of high-quality microbial APIs are prominent trends in this market.
The Microbial API Market segmentation, based on type, includes Antibody, Peptide, Protein, Small Molecule, and Vaccine. The antibody category generated the most income in 2023. The antibody segment of the microbial API market is concentrated on producing therapeutic antibodies via microbial fermentation techniques. These antibodies play a critical role in the fight against autoimmune illnesses and cancer. The increasing need for monoclonal antibodies, which are highly valued for their accuracy and effectiveness in targeted therapeutics, is an important development in this field.
The Microbial API Market segmentation, based on type, includes In-house and Outsourced. The outsourced category generated the most income in 2023. Many pharmaceutical companies have recently turned their attention to outside suppliers of manufacturing and research and development services. Pharmaceutical businesses are forced to rely heavily on outsourcing drug development processes due to the rise in demand for customized goods, the need for increased productivity and efficiency throughout the value chain, and ongoing pressure from regulatory bodies on drug pricing.
Figure 1: Microbial API Market, by Site, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Microbial API Market segmentation, based on end user, includes Pharmaceutical Companies, Biopharmaceutical Companies, and Others. The pharmaceutical companies category generated the most income in 2023 due to the significant need in the pharmaceutical industry for active pharmaceutical ingredients (APIs) derived from microbial fermentation. Due to the method's efficiency, scalability, and affordability, pharmaceutical companies use microbial fermentation techniques to generate a wide variety of APIs.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American microbial API market area will dominate this market because nations like the United States and Canada have highly developed healthcare infrastructures and high rates of healthcare spending. Significant domestic consumption of microbial API is fueled in part by the presence of major manufacturing and research and development (R&D) facilities of leading pharmaceutical companies in the area. In addition, the area has strict manufacturing and drug development regulations that guarantee businesses only purchase API from reputable providers, encouraging increased domestic production in North America.
Further, the major countries studied in the market report are the US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 2: MICROBIAL API MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe microbial API market accounts for the second-largest market share. The microbial API market has more chances due to rising healthcare costs. Key factors driving market expansion include rising R&D spending on drug development, the low production cost of microbial APIs, the growing generics market, and the rising prevalence of diseases like cancer. Further, the German microbial API market held the largest market share, and the UK microbial API market was the fastest growing market in the European region
The Asia-Pacific Microbial API Market is expected to grow at the fastest CAGR from 2024 to 2032. The microbial API consumption in Asia Pacific has increased due to a number of factors, including the fast expanding pharmaceutical industry in China and India, an infusion of foreign investments in production facilities, and the emergence of major domestic drug makers. Initiatives from the government to support homegrown manufacturing are also driving this region's market expansion. Moreover, China’s microbial API market held the largest market share, and the Indian microbial API market was the fastest growing market in the Asia-Pacific region.
Microbial API Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the microbial API market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, microbial API industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global microbial API industry to benefit clients and increase the market sector. In recent years, the microbial API industry has offered some of the most significant advantages to medicine. Major players in the microbial API market are attempting to increase market demand by investing in research and development operations includes Merck & Co., Inc., DSM, CSPC Pharmaceutical Group Limited, KOLON LIFE SCIENCE, Topfond Pharmaceutical Co., Ltd., Shandong Lukang Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and Lonza.
One provider of contract manufacturing and research solutions is Lonza Group Ltd. (Lonza). It provides services in clinical development, production, and commercial mammalian and microbial manufacturing. In addition, it provides high-potential active pharmaceutical components, sophisticated intermediates, cell and gene therapy capabilities, cell-culture models, genome editing, endotoxin products, research media, and testing goods. Lonza offers solutions for material protection, composites, and microbiological and hygienic management. Lonza announced intentions in August 2023 to invest a significant $500 million to improve its microbial fermentation capabilities at its site in Visp, Switzerland. Lonza will be able to increase production capacity for APIs and complicated biologics made from microbial fermentation thanks to this investment.
Teva Pharmaceutical Industries Ltd. is a company that finds, develops, produces, and sells specialty and generic medications. The company offers specialist medications to address a variety of medical diseases, including women's health, dermatological, cancer, respiratory, and central nervous system (CNS) illnesses. Generic medications are available in a range of dosage forms, such as tablets, capsules, liquids, inhalants, ointments, and injectables. In addition to active pharmaceutical ingredients (APIs), Teva also offers over-the-counter (OTC) drugs. It concentrates on creating generic medications as well.
Key Companies in the microbial API market include
Microbial API Industry Developments
November 2023: The pharmaceutical business Rusan Pharma Ltd., situated in Madhya Pradesh, India, has announced the opening of a new microbiological and traditional active pharmaceutical ingredient (API) manufacturing plant. About US$ 36.1 million has been invested by the corporation in its manufacturing facility.
August 2023: The American company Antheia, Inc., which produces pharmaceutical ingredients, has announced the successful completion of its first 116,000-liter manufacturing facility. This unit is capable of producing critical medicines for Antheia's pipeline by producing commercially relevant fermentation for the production of active pharmaceutical ingredients (APIs).
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 58.3 Billion |
| Market Size 2024 | USD 62.3 Billion |
| Market Size 2032 | USD 100.17 Billion |
| Compound Annual Growth Rate (CAGR) | 7.00% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Host, Type, Site, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea |
| Key Companies Profiled | Merck & Co., Inc., DSM, CSPC Pharmaceutical Group Limited, KOLON LIFE SCIENCE, Topfond Pharmaceutical Co., Ltd., Shandong Lukang Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and Lonza. |
| Key Market Opportunities | · Growing need for biosimilar and generic medications |
| Key Market Dynamics | · Rising consumer demand for biopharmaceutical goods such as therapeutic proteins and monoclonal antibodies · Rise in R&D efforts to provide novel vaccines and combination treatments |
Frequently Asked Questions (FAQ) :
The Microbial API Market size was valued at USD 58.3 Billion in 2023.
The global market is projected to grow at a CAGR of 7.00% during the forecast period, 2024-2032.
North America had the largest share in the global market.
The key players in the market are Merck & Co., Inc., DSM, CSPC Pharmaceutical Group Limited, KOLON LIFE SCIENCE, Topfond Pharmaceutical Co., Ltd., Shandong Lukang Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and Lonza, among others.
The antibody category dominated the market in 2023.
The outsourced category had the largest share in the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
